Major Clinical Response to Nivolumab in Relapsed/Refractory Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2015.346
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Functional Imaging Predicts Progression-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Relapsed/Refractory Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Low Dose PD-1 Inhibition in Relapsed Refractory Hodgkin Lymphoma After Allogeneic Stem Cell Transplant With Concomitant Active GVHD

British Journal of Haematology
Hematology
2018English

Haploidentical Hematopoietic Stem Cell Transplantation Compared With Hla-Matched Stem Cell Transplantation for Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pet-Adapted Nivolumab +/- Ice as Initial Salvage Therapy in Relapsed/Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy